Second-generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial

Robert Rosenheck, Marvin Swartz, Joseph Patrick McEvoy, T. Scott Stroup, Sonia Davis, Richard S.E. Keefe, John Hsiao, Jeffrey Lieberman

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


The cost-effectiveness component of the 18-month CATIE trial of schizophrenia ppharmacotherapy (n = 1460) showed that the first-generation antipsychotic pephenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number2
StatePublished - Apr 2007


  • Antipsychotics
  • Cost-effectiveness
  • Quality of life
  • Randomized trials schizophrenia

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)


Dive into the research topics of 'Second-generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial'. Together they form a unique fingerprint.

Cite this